Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future

被引：0
|
作者：
Calegari, M. A. [1 ]
Orlandi, A. [1 ]
Cocomazzi, A. [2 ]
Martini, M. [2 ]
Bagala, C. [1 ]
Indellicati, G. [1 ]
Zurlo, V. [1 ]
Monterisi, S. [1 ]
Di Dio, C. [1 ]
Barile, R. [1 ]
Di Salvatore, M. A. [1 ]
Basso, M. [1 ]
Cassano, A. [1 ]
Larocca, L. M. [2 ]
Barone, C. [3 ]
机构：
[1] Univ Cattolica Sacro Cuore, Oncol Med, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Anat Patol, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.164
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页数：1
相关论文
共 50 条
  • [31] hENT1 expression in human urothelium; evaluating hENT1 prognostic potential for intravesical Gemcitabine treatment outcome in patients with superficial urothelial carcinoma
    Melbourne, W.
    Tran, K.
    Johnson, L. A.
    De Souza, P.
    Lynch, W. J.
    BJU INTERNATIONAL, 2012, 109 : 40 - 40
  • [32] Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
    Poplin, Elizabeth
    Wasan, Harpreet
    Rolfe, Lindsey
    Raponi, Mitch
    Ikdahl, Tone
    Bondarenko, Ihor
    Davidenko, Irina
    Bondar, Volodymyr
    Garin, August
    Boeck, Stefan
    Ormanns, Steffen
    Heinemann, Volker
    Bassi, Claudio
    Evans, T. R. Jeffrey
    Andersson, Roland
    Hahn, Hejin
    Picozzi, Vince
    Dicker, Adam
    Mann, Elaina
    Voong, Cynthia
    Kaur, Paramjit
    Isaacson, Jeff
    Allen, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4453 - 4461
  • [33] Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma
    Chapman, Brandon C.
    Gleisner, Ana
    Rigg, Devin
    Messersmith, Wells
    Paniccia, Alessandro
    Meguid, Cheryl
    Gajdos, Csaba
    McCarter, Martin D.
    Schulick, Richard D.
    Edil, Barish H.
    JOURNAL OF THE PANCREAS, 2018, 19 (02): : 75 - 85
  • [34] hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
    Aughton, Karen
    Elander, Nils O.
    Evans, Anthony
    Jackson, Richard
    Campbell, Fiona
    Costello, Eithne
    Halloran, Christopher M.
    Mackey, John R.
    Scarfe, Andrew G.
    Valle, Juan W.
    Carter, Ross
    Cunningham, David
    Tebbutt, Niall C.
    Goldstein, David
    Shannon, Jennifer
    Glimelius, Bengt
    Hackert, Thilo
    Charnley, Richard M.
    Anthoney, Alan
    Lerch, Markus M.
    Mayerle, Julia
    Palmer, Daniel H.
    Buechler, Markus W.
    Ghaneh, Paula
    Neoptolemos, John P.
    Greenhalf, William
    CANCERS, 2021, 13 (22)
  • [35] Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
    Marechal, R.
    Bachet, J.
    Mackey, J. R.
    Demetter, P.
    Graham, K.
    Couvelard, A.
    Svrcek, M.
    Bardier, A.
    Hammel, P.
    Sauvanet, A.
    Louvet, C.
    Paye, F.
    Rougier, P.
    Hannoun, L.
    Andre, T.
    Dumontet, C. M.
    Cass, C. E.
    Salmon, I.
    Emile, J.
    Van Laethem, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
    Borbath, I.
    Verbrugghe, L.
    Lai, R.
    Gigot, J. F.
    Humblet, Y.
    Piessevaux, H.
    Sempoux, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) : 990 - 996
  • [37] Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma
    Boeck, Stefan Hubert
    Raponi, Mitch
    Richardson, William
    Towne, Penny
    Isaacson, Jeffrey D.
    Ranger-Moore, Jim
    Powell, Eric
    Clements, June
    Feng, Janine D.
    McElhinny, Abigail
    Ormanns, Steffen
    Kirchner, Thomas
    Regine, William
    Winter, Kathryn A.
    Ansari, Daniel
    Rolfe, Lindsey
    Allen, Andrew R.
    Andersson, Roland
    Heinemann, Volker
    Dicker, Adam P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials
    Neoptolemos, John P.
    Greenhalf, William
    Ghaneh, Paula
    Palmer, Daniel H.
    Cox, Trevor F.
    Garner, Elizabeth
    Campbell, Fiona
    Mackey, John Robert
    Moore, Malcolm J.
    Valle, Juan W.
    Mcdonald, Alec
    Tebbutt, Niall C.
    Dervenis, Christos
    Glimelius, Bengt
    Charnley, Richard M.
    Lacaine, Francois
    Mayerle, Julia
    Rawcliffe, Charlotte Louise
    Bassi, Claudio
    Buchler, Markus W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Predictive value of hENT1 immunohistochemistry for gemcitabine-treated pancreatic cancer is antibody dependent.
    Yusuf, Dimas
    Lui, Arthur
    Abdelaziz, Zainab
    Spratlin, Jennifer L.
    Mackey, John Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Can hENT1 Expression in EUS-FNAB Samples be the Prognostic Factor of Pancreatic Ductal Adenocarcinoma Before Gemcitabine-based Chemoradiotherapy?
    Yamada, R.
    Mizuno, S.
    Inoue, H.
    Murata, Y.
    Kuriyama, N.
    Azumi, Y.
    Kishiwada, M.
    Usui, M.
    Sakurai, Y.
    Isaji, S.
    PANCREAS, 2014, 43 (08) : 1425 - 1425
12345